John C. Riches

Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation

Meghana Rajendraprasad, John C. Riches

gb (code pays fourni par la source)

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia

Renata Walewska, Toby A. Eyre, Adrian Bloor, G. Follows et autres

gb (code pays fourni par la source)

Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection

Lotte C.A. Stiekema, Hsuan Chou, Amy Craster, Bela Wrench et autres

gb (code pays fourni par la source)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Ioannis Mantzaris, William A. Wood, Lydia Scarfò, Rushad Patell et autres

us (code pays fourni par la source)

The impact of real-time feedback on ventilation quality during out-of-hospital cardiac arrest: A before-and-after study

Ian R. Drennan, M.K. Lee, Jean-Philippe Héroux, Andrew Lee et autres

ca, us (code pays fourni par la source)

CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Kim Linton, Graham P. Collins, Francesco Forconi, Nirav N. Shah et autres

gb, us, nl (code pays fourni par la source)

Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Kim Linton, Graham P. Collins, Francesco Forconi, Nirav N. Shah et autres

gb, us, nl (code pays fourni par la source)

Night sweats and haematological malignancies: Are ‘sweats’ truly a ‘red flag’ symptom? An insight into 2-week-wait haemato-oncology referrals at St Bartholomew's Hospital, London, UK

Carola Maria Bigogno, John C. Riches, Rifca Le Dieu

gb (code pays fourni par la source)

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia

Manabu Hayama, John C. Riches

gb (code pays fourni par la source)

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma

Annalisa D’Avola, Nathalie Legrave, Mylène Tajan, Probir Chakravarty et autres

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton, Alexey V. Danilov et autres

gb, us (code pays fourni par la source)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

Kim Linton, Francesco Forconi, David Lewis, John C. Riches et autres

gb, us (code pays fourni par la source)